MX2019006773A - Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros. - Google Patents
Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.Info
- Publication number
- MX2019006773A MX2019006773A MX2019006773A MX2019006773A MX2019006773A MX 2019006773 A MX2019006773 A MX 2019006773A MX 2019006773 A MX2019006773 A MX 2019006773A MX 2019006773 A MX2019006773 A MX 2019006773A MX 2019006773 A MX2019006773 A MX 2019006773A
- Authority
- MX
- Mexico
- Prior art keywords
- medetomidine
- dexmedetomidine
- dogs
- separation anxiety
- treatment
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 208000000810 Separation Anxiety Diseases 0.000 title abstract 2
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 title abstract 2
- 229960004253 dexmedetomidine Drugs 0.000 title abstract 2
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002140 medetomidine Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a dexmedetomidina, medetomidina o una sal farmacéuticamente aceptable de los mismos para uso en un método para tratar la ansiedad por separación en animales de compañía, particularmente perros, que comprende administrar a un individuo que lo necesite una cantidad eficaz de dicho compuesto como ingrediente activo. El ingrediente activo se administra preferiblemente por vía oral, por ejemplo en forma de un gel para administración por oromucosa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20165960 | 2016-12-13 | ||
| PCT/FI2017/050880 WO2018109272A1 (en) | 2016-12-13 | 2017-12-12 | Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019006773A true MX2019006773A (es) | 2019-08-22 |
| MX389589B MX389589B (es) | 2025-03-20 |
Family
ID=60957335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006773A MX389589B (es) | 2016-12-13 | 2017-12-12 | Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20200069650A1 (es) |
| EP (1) | EP3554501B1 (es) |
| JP (1) | JP7065871B2 (es) |
| KR (2) | KR20240096833A (es) |
| CN (1) | CN110072524A (es) |
| AU (1) | AU2017378203B2 (es) |
| DK (1) | DK3554501T3 (es) |
| ES (1) | ES2879298T3 (es) |
| HR (1) | HRP20211310T1 (es) |
| HU (1) | HUE055565T2 (es) |
| LT (1) | LT3554501T (es) |
| MX (1) | MX389589B (es) |
| PL (1) | PL3554501T3 (es) |
| PT (1) | PT3554501T (es) |
| RU (1) | RU2759726C2 (es) |
| SI (1) | SI3554501T1 (es) |
| WO (1) | WO2018109272A1 (es) |
| ZA (1) | ZA201904591B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018126182A1 (en) | 2016-12-31 | 2018-07-05 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| KR102824967B1 (ko) | 2018-06-27 | 2025-06-25 | 바이오엑셀 테라퓨틱스 인코포레이티드 | 덱스메데토미딘을 함유하는 필름 제형 및 이를 생산하는 방법 |
| KR20220049526A (ko) | 2019-07-19 | 2022-04-21 | 바이오엑셀 테라퓨틱스 인코포레이티드 | 비-진정성 덱스메데토미딘 치료 양생법 |
| CA3212436A1 (en) | 2021-03-19 | 2022-09-22 | Johanna KUJALA | Tasipimidine formulations and use thereof |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI864570A0 (fi) * | 1986-11-11 | 1986-11-11 | Farmos Oy | Terapeutiskt anvaendbar foerening. |
| JP4438256B2 (ja) | 2001-06-29 | 2010-03-24 | 味の素株式会社 | 動伴侶動物における問題行動を防止するための医薬組成物および方法 |
| US20110021588A1 (en) | 2009-05-15 | 2011-01-27 | Recro Pharma, Inc. | Sublingual dexmeditomidine compositions and methods of use thereof |
| HRP20180479T1 (hr) * | 2012-10-15 | 2018-05-04 | Orion Corporation | Veterinarski postupak za ublažavanje averzije prema buci |
-
2017
- 2017-12-12 DK DK17828942.7T patent/DK3554501T3/da active
- 2017-12-12 EP EP17828942.7A patent/EP3554501B1/en active Active
- 2017-12-12 CN CN201780076704.9A patent/CN110072524A/zh active Pending
- 2017-12-12 PT PT178289427T patent/PT3554501T/pt unknown
- 2017-12-12 HR HRP20211310TT patent/HRP20211310T1/hr unknown
- 2017-12-12 US US16/468,707 patent/US20200069650A1/en not_active Abandoned
- 2017-12-12 AU AU2017378203A patent/AU2017378203B2/en active Active
- 2017-12-12 LT LTEPPCT/FI2017/050880T patent/LT3554501T/lt unknown
- 2017-12-12 HU HUE17828942A patent/HUE055565T2/hu unknown
- 2017-12-12 ES ES17828942T patent/ES2879298T3/es active Active
- 2017-12-12 RU RU2019121690A patent/RU2759726C2/ru active
- 2017-12-12 SI SI201730829T patent/SI3554501T1/sl unknown
- 2017-12-12 PL PL17828942T patent/PL3554501T3/pl unknown
- 2017-12-12 KR KR1020247019196A patent/KR20240096833A/ko active Pending
- 2017-12-12 MX MX2019006773A patent/MX389589B/es unknown
- 2017-12-12 KR KR1020197020353A patent/KR20190096376A/ko not_active Ceased
- 2017-12-12 WO PCT/FI2017/050880 patent/WO2018109272A1/en not_active Ceased
- 2017-12-12 JP JP2019551751A patent/JP7065871B2/ja active Active
-
2019
- 2019-07-12 ZA ZA2019/04591A patent/ZA201904591B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7065871B2 (ja) | 2022-05-12 |
| NZ755354A (en) | 2024-11-29 |
| KR20240096833A (ko) | 2024-06-26 |
| EP3554501B1 (en) | 2021-06-09 |
| ES2879298T3 (es) | 2021-11-22 |
| AU2017378203A1 (en) | 2019-07-25 |
| CA3046286A1 (en) | 2018-06-21 |
| EP3554501A1 (en) | 2019-10-23 |
| JP2020500944A (ja) | 2020-01-16 |
| WO2018109272A1 (en) | 2018-06-21 |
| CN110072524A (zh) | 2019-07-30 |
| AU2017378203B2 (en) | 2022-12-08 |
| RU2759726C2 (ru) | 2021-11-17 |
| HRP20211310T1 (hr) | 2021-11-26 |
| PL3554501T3 (pl) | 2021-12-06 |
| ZA201904591B (en) | 2025-10-29 |
| US20200069650A1 (en) | 2020-03-05 |
| HUE055565T2 (hu) | 2021-11-29 |
| KR20190096376A (ko) | 2019-08-19 |
| MX389589B (es) | 2025-03-20 |
| DK3554501T3 (da) | 2021-07-19 |
| LT3554501T (lt) | 2021-07-12 |
| PT3554501T (pt) | 2021-07-05 |
| RU2019121690A (ru) | 2021-01-15 |
| RU2019121690A3 (es) | 2021-04-07 |
| SI3554501T1 (sl) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| SV2018005682A (es) | Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX2019006773A (es) | Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros. | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| CO2018009561A2 (es) | Métodos para tratar la depresión con antagonistas del receptor de orexina-2 | |
| UY36207A (es) | Inhibidores de la syk | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CR20160527A (es) | Derivados de carboxamida | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| DOP2019000070A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| PE20151607A1 (es) | Formulaciones de compuestos organicos | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| UY36123A (es) | Derivados de carboxamida | |
| AR088204A1 (es) | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina | |
| DOP2019000071A (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos | |
| AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
| MX378409B (es) | Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa. | |
| DOP2013000004A (es) | Agentes terapeuticos 976 | |
| AR097890A1 (es) | Compuestos de urea |